News & Statements
A Call for Modern Patient-Centered Type 1 Diabetes Treatment Guidelines
15 May 2026, 1:13 p.m. in News & Statements by T1International
T1International is urging the World Health Organization to include insulin analogues and insulin pens in its Type 1 Diabetes Treatment Guidelines to promote safer, more flexible, and more equitable diabetes care worldwide. The statement argues that these modern treatments improve quality of life, dosing accuracy, dignity, and health outcomes, while highlighting the inequities faced by people in low- and middle-income countries who often lack access to them. It also emphasizes the importance of including the lived experiences of people with diabetes in global healthcare policymaking to ensure treatment standards reflect both clinical evidence and real-world needs. Read more
Patients Win: How #insulin4all Advocates Helped make insulin more affordable
6 Apr 2026, 3:07 p.m. in #insulin4all USA, News & Statements by T1International
Insulin has long been unaffordable for many people in the United States, even though the cost to produce most insulin vials remains between $3 and $6. Over the past few decades, prices have skyrocketed, with “the Big Three” insulin manufacturers, Eli Lilly, Novo Nordisk, and Sanofi, controlling nearly all of the U.S. insulin market and raising prices in lockstep. Thanks to persistent advocacy and legal action, we have won a significant victory in holding intermediaries accountable for practices that drove up insulin costs.
Read more
Our Plan for 2026: The Year of Public Pharma
15 Jan 2026, 4:47 p.m. in News & Statements by T1International
2026 will be the year of Public Pharma.
Public Pharma is the idea that essential medicines, like clean drinking water or education of young people, should serve the public good rather than private profit. It recognizes that health is a human right, not a commodity, and that governments have both the responsibility and the capacity to produce medicines that people need at prices they can afford. Read more
T1International Year in Review: 2025
18 Dec 2025, 8:23 p.m. in #insulin4all USA, Global Stories, News & Statements by T1International
Throughout 2025, T1International’s global network advanced critical work to improve access to insulin and diabetes supplies. Across regions, our community organized events, met with legislators, shared their experiences, and pushed for structural change.
Read more
New $55 Insulin Pens Mark Step in California’s Fight Against Insulin Price Gouging
7 Oct 2025, 10:40 p.m. in #insulin4all USA, News & Statements by T1International
The state of California will take significant steps forward to increase insulin access and affordability – beginning January 1, 2026, CalRx will offer a box of five insulin pens for $55 to anyone who needs it. California announced that Civica will contract with India-based biosimilar manufacturer Biocon to fulfill its commitment to bring low-cost insulin glargine (a long-acting and not name-brand insulin) to California through the CalRx label. Read more
Fixing a Broken System: The Path to Public Pharma in New York
6 Oct 2025, 11 p.m. in #insulin4all USA, News & Statements by T1International
On Thursday, September 25, 2025, T1International brought policy leaders, advocates, and patients together at NYU Law for “Fixing a Broken System: The Path to Public Pharma in New York,” a major public event highlighting the urgent need for publicly controlled pharmaceutical production to counter skyrocketing drug prices. Read more
Our Strategic Plan: Building a movement for Accessible, Affordable, and Equitable Diabetes Care
6 Oct 2025, 8:12 p.m. in #insulin4all USA, News & Statements by T1International
At T1International, over a decade of grassroots organizing, storytelling, advocacy, and action have brought us to this critical moment. Our community has grown to include people with diabetes, caregivers, and allies from over 150 countries, all united by a shared vision: a world where everyone has the access to the insulin, supplies, and care they need to survive and truly live. Read more
World Health Organization Approves Rapid-Acting Insulin Analogues to the 24th EML
5 Sep 2025, 2:56 p.m. in Global Stories, News & Statements by T1International
Global Diabetes Advocates Urge Novo Nordisk’s New CEO to Prioritize People Over Profits
7 Aug 2025, 8:27 p.m. in #insulin4all USA, Global Stories, News & Statements by T1International
T1International statement regarding largest cuts to healthcare coverage in American History.
3 Jul 2025, 8:45 p.m. in #insulin4all USA, News & Statements by T1International
The recently passed “One Big Beautiful Bill” represents the largest and greatest healthcare loss in American history, cutting health care for 17 million people living in this country. This bill, passed in the United States Congress today, is a profound and deadly cut for people living with diabetes, their families, and marginalized and disabled people across the country.
Read more